Positron emission tomography/computed tomography (PET/CT) after administration of zirconium-89 (89Zr) labeled trastuzumab allows the detection of tumor lesions overexpressing HER2 in patients with HER2-positive breast cancer10, potentially serving as a complementary tool for treatment decision making and patient management11. Here, ERBB2 is linked to neoplasm.